newsfilter
← Latest News
GlobeNewswire·

Sonnet BioTherapeutics Reports Fiscal Year 2024 Financial Results and Provides Corporate Update

Continued progress with both clinical trials of lead program, SON-1010, for solid tumors and Platinum-Resistant Ovarian Cancer (PROC) Executed licensing agreement to support initiation of a Phase 2 clinical trial of